Paraneoplastic Pemphigus (PNP) / Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS): Comprehensive Research Report

1. Disease Information

Overview: Paraneoplastic pemphigus (PNP), also increasingly termed paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare, highly fatal autoimmune mucocutaneous blistering disease that arises in patients with an underlying benign or malignant neoplasm — most commonly a lymphoproliferative disorder. First described by Anhalt et al. in 1990, it is immunologically and clinically distinct from other pemphigus variants, defined by circulating autoantibodies against desmosomal cadherins (desmogleins 1 and 3) and the plakin family of cytoskeletal-linker proteins, combined with a strong cell-mediated (cytotoxic T-cell) component. The term PAMS, proposed in 2001, was introduced to capture the disease's polymorphous mucocutaneous presentation, immunologic abnormalities, and potential for multi-organ (notably pulmonary) involvement, distinguishing it from "classic" pemphigus that happens to co-occur with a tumor (StatPearls; JAAD Part I, PMID:37597771).

Key identifiers: | Resource | ID | |---|---| | MONDO | MONDO:0018974 | | Orphanet | ORPHA:63455 | | ICD-11 | EB40.2 | | ICD-10-CM | L10.81 | | OMIM | Not listed (not a monogenic/Mendelian disorder) | | MeSH | Pemphigus, subheading "Paraneoplastic" (D016883 parent) |

Sources: Orphanet, ICD10Data, Wikidata Q1394580

Synonyms: Paraneoplastic autoimmune multiorgan syndrome (PAMS); PNP; paraneoplastic autoimmune bullous disease.

Evidence base: Because PNP is exceedingly rare, virtually all data derive from aggregated case reports, case series, and retrospective cohort studies (largest series ~144–149 patients) rather than large prospective EHR-derived cohorts; there are no population-based registries.

2. Etiology

Disease Causal Factors

PNP is not caused by a germline mutation; it is a tumor-triggered autoimmune syndrome. An underlying neoplasm — most often lymphoproliferative — is believed to trigger aberrant B-cell and T-cell responses that cross-react with epithelial adhesion-complex proteins (molecular mimicry / epitope spreading hypothesis), producing pathogenic autoantibodies and autoreactive cytotoxic T cells (StatPearls; JAAD Part I).

Associated Neoplasms (Risk Factor: presence of these tumors)

Across pooled case series, the underlying neoplasm distribution is approximately: - Non-Hodgkin lymphoma — 38.6% (largest series with hematologic malignancy: 52.78%) - Chronic lymphocytic leukemia (CLL) — 18.4% (up to 22.92% in some series) - Castleman disease — 18.4% (up to 18.60%); this is the dominant association in children and adolescents, given Castleman disease's rarity in the general population but disproportionate co-occurrence with pediatric PNP - Thymoma — 5.5% - Waldenström macroglobulinemia — 1.2% - Hodgkin lymphoma — 0.6% - Monoclonal gammopathy — 0.6% - Solid tumors: follicular dendritic cell sarcoma, squamous cell carcinoma, and carcinomas of lung, stomach, colon

Lymphoproliferative neoplasms overall account for ~84% of PNP cases (StatPearls). In ~30% of cases, PNP is the first clinical manifestation of an occult neoplasm, meaning the skin/mucosal disease precedes cancer diagnosis. Sources: PMC11587122, Risk factors for death and survival, PMID:30981429.

Genetic Risk Factors

• HLA-DRB1*03 — associated with increased PNP susceptibility in French Caucasian populations
• HLA-Cw*14 — associated in Chinese populations
• In Chinese Han patients, HLA-B*4002/B*4004, B*51, B*52, Cw*14, DQB1*0301, DRB1*08, and DRB1*11 were relatively enriched versus controls
• Notably, HLA-DR4 and DR1/DR14, which confer risk for pemphigus vulgaris and pemphigus foliaceus, show no association with PNP — underscoring PNP's distinct immunogenetic basis from classic pemphigus

Source: PMC7341728, "Beyond the HLA polymorphism"; StatPearls.

Environmental / Age / Sex Risk Factors

• Age: typical onset 45–70 years (mean ~64.7 years); pediatric cases occur, strongly linked to Castleman disease
• Sex: roughly equal male:female distribution (no strong sex predilection reported)
• No established toxin, occupational, or infectious trigger independent of the neoplasm itself

Protective Factors

No specific genetic or environmental protective factors have been established in the literature; this is consistent with PNP's status as a rare, tumor-driven paraneoplastic syndrome rather than a polygenic/environmentally-modulated common disease.

Gene-Environment Interactions

Not well characterized beyond the HLA-neoplasm relationship above; the operative model is that neoplasm-driven immune dysregulation (particularly IL-6-producing lymphoproliferative tissue, as in Castleman disease) interacts with HLA-restricted antigen presentation to drive autoreactive B- and T-cell clones.

3. Phenotypes

Mucosal (earliest and most consistent feature)

PNP "almost always presents with early mucosal involvement," typically severe, painful, treatment-refractory oral mucosal erosions/ulcerations that may be the sole presenting sign. Involvement can extend to the vermilion border, tongue, oropharynx, nasopharynx, esophagus, conjunctiva, and anogenital mucosa (StatPearls). - Suggested HPO terms: HP:0032247 (Oral mucosal blister-like lesion) / HP:0002745 (Ulcerated skin lesion) — oral erosions specifically map best to general mucosal ulceration/erosion terms; conjunctival scarring maps to HP:0007957 (corneal/conjunctival scarring-type terms) or HP:0000581 (Blepharophimosis-adjacent conjunctival terms; more precisely conjunctival scarring/symblepharon).

Cutaneous — Five Clinical Subtypes (polymorphous)

1. Pemphigus-like: flaccid vesicles/bullae, crusted erosions (intraepidermal/suprabasal acantholysis)
2. Pemphigoid-like: tense subepidermal blisters, scaling erythematous plaques
3. Erythema multiforme-like (most common presentation, ~56%): polymorphic targetoid/erythematous lesions with dyskeratosis
4. Graft-versus-host disease-like: diffuse dusky, scaly papules
5. Lichen planus-like: violaceous flat-topped papules with lichenoid infiltrate

Source: StatPearls; DermNet.

Extracutaneous/Multi-organ Involvement (the "multiorgan" in PAMS)

• Ocular: up to 70% of patients; pseudomembranous conjunctivitis, progressive cicatrizing conjunctival scarring, corneal erosion, pterygium — potential for irreversible blindness
• Pulmonary: 59.1–92.8% of cases; dyspnea, dry cough, obstructive lung disease progressing to bronchiolitis obliterans (incidence estimates 27–93% across studies) — a leading cause of death
• Myasthenic symptoms: 39% of studied patients report symptoms; 35% meet criteria for myasthenia gravis by anti-acetylcholine-receptor antibody titer, especially with thymoma-associated PNP
• Gastrointestinal: esophageal erosions, dysphagia
• Additional reported organ involvement: thyroid, kidney

Source: StatPearls; PMC11277726 (airway involvement).

Laboratory/Immunologic Abnormalities

Circulating autoantibodies against plakin-family proteins and desmogleins (see Section 4); elevated inflammatory markers related to the underlying lymphoproliferative disease.

Phenotype Characteristics

• Onset: adult (45–70y peak) but can occur in children/adolescents (Castleman-associated)
• Severity: variable but generally severe; extensive mucocutaneous involvement is an adverse prognostic sign
• Progression: often relapsing/progressive; cutaneous lesions may improve within ~12 weeks of treatment, but mucosal disease is frequently refractory
• Frequency of specific manifestations: erythema multiforme-like cutaneous pattern in 56%; ocular in up to 70%; pulmonary in 59–93%; myasthenic symptoms in 39%

Quality of Life Impact

Severe painful oral erosions impair eating/nutrition (frequently requiring nasogastric feeding); ocular scarring can cause permanent visual impairment; bronchiolitis obliterans causes progressive, often fatal, respiratory disability; extensive skin denudation requires burn-unit–level wound care and carries infection/sepsis risk.

Suggested HPO terms for pathophysiology-related phenotypes: HP:0200042 (Skin ulcer), HP:0100836 (Blistering) type terms, HP:0002206 (Pulmonary fibrosis/obliterans-adjacent — bronchiolitis obliterans itself has no precise dedicated HPO term but maps near obstructive lung disease terms), HP:0000546 (Blindness), HP:0003324 (Generalized muscle weakness — myasthenic).

4. Genetic/Molecular Information

PNP is not a Mendelian genetic disease — there is no single causal gene. Instead, disease-defining molecular features are the autoantibody targets:

Target Antigens (Plakin Family + Desmosomal Cadherins)

Sources: PMC6558011; PMC9332891 — anti-desmoplakin C-terminus antibodies induce acantholysis in vivo; Frontiers 10.3389/fimmu.2022.886226.

Functional Consequence

Plakin proteins are cytolinkers connecting the keratin intermediate filament cytoskeleton to desmosomes and hemidesmosomes. Autoantibody binding — particularly against the desmoplakin C-terminus — directly disrupts desmosomal adhesion, producing acantholysis (loss of keratinocyte cell-cell adhesion), demonstrated experimentally in murine models (dose-dependent blister/acantholysis induction and keratinocyte apoptosis after antibody injection in neonatal mice).

Modifier/Susceptibility Genes

HLA-DRB1*03 (Caucasian), HLA-Cw*14 (Chinese) — see Section 2.

Epigenetics / Chromosomal Abnormalities

Not specifically characterized for PNP; the underlying lymphoproliferative neoplasm (e.g., CLL, follicular lymphoma) may carry its own somatic cytogenetic lesions (e.g., t(14;18) in follicular lymphoma), but these are neoplasm-intrinsic rather than PNP-defining.

Suggested gene/protein annotation terms (HGNC): DSP (desmoplakin), EVPL (envoplakin), PPL (periplakin), DST/BPAG1 (BP230/dystonin), PLEC (plectin), PKP1-3 (plakophilins, less characteristic), DSG1, DSG3, A2ML1.

5. Environmental Information

There is no established environmental toxin, radiation, or occupational exposure directly implicated in PNP etiology. The dominant "environmental" trigger, functionally, is the presence of the associated neoplasm itself (see Section 2), which is presumed to drive antigen release/molecular mimicry and cytokine-driven (e.g., IL-6, particularly relevant in Castleman disease) immune dysregulation. No specific infectious agent has been established as causal for PNP itself (distinct from its associated neoplasms, some of which — e.g., certain lymphomas — may have viral associations such as EBV, though this is not PNP-specific).

6. Mechanism / Pathophysiology

Causal Chain (Trigger → Manifestation)

1. Underlying neoplasm (lymphoproliferative disorder, thymoma, or Castleman disease) → dysregulated B- and T-cell immunity
2. Autoantibody production against plakin-family desmosomal/hemidesmosomal linker proteins (envoplakin, periplakin, desmoplakins, BP230, plectin, epiplakin) and desmogleins (Dsg1/Dsg3) — proposed mechanism includes molecular mimicry between tumor antigens and epithelial adhesion proteins
3. Autoantibody binding disrupts desmosome-cytoskeleton linkage → acantholysis (intraepidermal keratinocyte separation) — directly demonstrated for anti-desmoplakin C-terminus antibodies in vivo (murine skin) and in vitro
4. Concurrent cell-mediated cytotoxicity: autoreactive CD4+ and CD8+ T cells (including a Th17-skewed, T follicular helper-like Dsg3-reactive population) infiltrate lesional tissue, producing interface dermatitis with keratinocyte apoptosis/necrosis — a histologic and mechanistic feature that distinguishes PNP from antibody-only-mediated pemphigus vulgaris
5. Multi-organ epithelial targeting: because plakins/desmosomes are expressed broadly across stratified and transitional epithelia (skin, oral/esophageal mucosa, conjunctiva) and — critically — in bronchial epithelium, the same autoimmune attack extends to the respiratory tract, producing bronchiolitis obliterans (epiplakin autoantibodies specifically implicated), the dominant driver of PNP mortality.

Molecular/Cellular Processes

• Loss of keratinocyte-keratinocyte adhesion (desmosome disruption)
• Keratinocyte apoptosis/necrosis (dyskeratosis)
• Basal layer vacuolization (interface dermatitis pattern)
• Lymphocytic exocytosis into epithelium
• Bronchiolar epithelial injury, fibrosis, and obliteration (bronchiolitis obliterans) — lung biopsy shows bronchiole fibrosis, dense lymphohistiocytic infiltrates, and autoantibody deposition

Suggested GO terms: GO:0007156 (homophilic cell adhesion via plasma membrane adhesion molecules), GO:0030057 (desmosome), GO:0006915 (apoptotic process), GO:0002250 (adaptive immune response), GO:0042113 (B cell activation).

Suggested CL terms: CL:0000312 (keratinocyte), CL:0000000 downstream — specifically stratified squamous epithelial cell; CL:0000784 (plasmacytoid... not applicable) — better: CL:0000542 (lymphocyte), CL:0000625 (CD8-positive alpha-beta T cell), CL:0000546 (T-helper cell).

Suggested UBERON terms: UBERON:0001003 (skin epidermis), UBERON:0001744 (tonsil/oral mucosa-adjacent), UBERON:0006562 (oral mucosa), UBERON:0002185 (bronchiole), UBERON:0001772 (conjunctiva).

Molecular Profiling / Advanced Technologies

The literature on PNP is dominated by immunoprecipitation/immunoblot and ELISA-based antigen characterization rather than modern multi-omic (transcriptomic/proteomic/single-cell) profiling; no major GEO/single-cell atlas datasets specific to PNP were identified in this search. This represents a notable data gap relative to other autoimmune skin diseases.

Source: PMC6558011; PMC9332891; JCI 29403 — Dsg3-specific CD4+ T cells induce pemphigus and interface dermatitis in mice; PMC10107879 — T cell autoimmunity to Dsg3.

7. Anatomical Structures Affected

• Organ level: skin (epidermis), oral cavity, oropharynx, nasopharynx, esophagus, conjunctiva/cornea, anogenital mucosa, lungs/bronchioles, and (via associated myasthenia gravis) neuromuscular junction; kidney and thyroid involvement reported less commonly
• Body systems: integumentary, mucosal/gastrointestinal, ocular, respiratory, and (secondarily) neuromuscular
• Tissue/cell level: stratified squamous epithelium (skin, oral mucosa, esophagus, conjunctiva), transitional epithelium (bladder — relevant diagnostically, see Section 10), bronchiolar epithelium; keratinocytes are the principal targeted cell population
• Subcellular: desmosomes and hemidesmosomes (cell junction complexes); keratin intermediate filament cytoskeleton
• Localization: bilateral/diffuse, non-lateralized involvement typical

Suggested UBERON: UBERON:0001003 (epidermis), UBERON:0006562 (oral mucosa), UBERON:0001043 (esophagus), UBERON:0001772 (conjunctiva), UBERON:0002185 (bronchiole), UBERON:0001255 (urinary bladder — diagnostic substrate).

8. Temporal Development

• Onset: adult, typically 45–70 years; pediatric onset associated with Castleman disease; onset is typically subacute, beginning with refractory oral mucositis
• Progression: cutaneous lesions may resolve within ~12 weeks of treatment; mucosal lesions are frequently persistent/poorly responsive; pulmonary disease (bronchiolitis obliterans) is often progressive and irreversible
• Disease course pattern: variable — can be relapsing or steadily progressive; "there is not always a parallel evolution between PNP severity and the malignancy's treatment response," meaning cutaneous/mucosal/pulmonary disease can progress even after successful cancer treatment (StatPearls)
• Duration: chronic when survived; however most patients die within one year of diagnosis
• Remission: possible with successful resection/treatment of a benign underlying tumor (e.g., Castleman disease, localized thymoma), which offers the best prognosis

9. Inheritance and Population

Epidemiology

• PNP accounts for only 3–5% of all pemphigus cases (pemphigus overall is itself rare)
• No formal population-based incidence/prevalence rate has been established (extremely rare disease, case-series-based literature only)

Inheritance

• Not a Mendelian inherited disease — no defined inheritance pattern (AD/AR/X-linked); susceptibility is polygenic/immunogenetic (HLA-associated) combined with an acquired triggering neoplasm
• No known penetrance, expressivity, anticipation, mosaicism, or carrier-frequency concepts apply, as this is an acquired paraneoplastic autoimmune disease, not a germline genetic disorder

Population Demographics

• Sex ratio: approximately equal (M:F ~1:1)
• Age distribution: mean age at diagnosis ~64.7 years in adult series; a distinct pediatric/adolescent cluster exists, driven by Castleman disease association
• Ethnic/geographic variation is reflected mainly in differing HLA-risk-allele profiles (Caucasian: DRB1*03; Chinese: Cw*14 and related alleles) rather than differential prevalence data

Sources: StatPearls; PMC7341728.

10. Diagnostics

Diagnostic Criteria Frameworks

Three overlapping criteria systems are used:

1. Anhalt's original criteria (5 components): - Clinical: painful mucosal erosions ± polymorphous cutaneous lesions with an underlying malignancy - Histopathology: suprabasal acantholysis, interface dermatitis, keratinocyte necrosis - Direct immunofluorescence (DIF): IgG/C3 in intercellular spaces ± basement membrane zone - Indirect immunofluorescence (IIF) on rat/murine bladder transitional epithelium - Immunoprecipitation: characteristic plakin protein pattern (250, 230, 210, 190, 170 kDa bands)

2. Joly criteria (high specificity 84–100%, sensitivity 82–86%): (a) underlying lymphoproliferative disorder, (b) IIF-positive on rat bladder, (c) anti-periplakin/anti-envoplakin autoantibodies by immunoblot.

3. Camisa and Helm major/minor criteria: requires 3 major, or 2 major + 2 minor criteria (major: polymorphic mucocutaneous eruption, concomitant neoplasm, characteristic immunoprecipitation pattern; minor: histologic acantholysis, DIF pattern, positive rat bladder IIF).

Key Test Characteristics

• DIF can be negative in up to 50% of cases — a negative DIF does NOT exclude PNP
• IIF on rodent/murine bladder: sensitivity ~75%, specificity ~83%; negative/indeterminate in up to one-fourth of patients — an adequate screening test but not conclusive alone; useful for discriminating PNP from pemphigus vulgaris/foliaceus (which are typically negative on this substrate)
• Immunoblot is considered the gold standard, detecting anti-envoplakin (210 kDa)/anti-periplakin (190 kDa) reactivity with high sensitivity/specificity
• ELISA assays for anti-envoplakin/anti-periplakin antibodies are also available and increasingly used

Additional Malignancy Workup

Once PNP is suspected: CBC, LDH, flow cytometry, and cross-sectional imaging (chest/abdomen/pelvis) to identify an occult neoplasm.

Differential Diagnosis

Stevens-Johnson syndrome/toxic epidermal necrolysis (erythema multiforme-like PNP is often mistaken for these), erythema multiforme, lichen planus, graft-versus-host disease, HSV infection, drug-induced pemphigus, pemphigus vulgaris, mucous membrane pemphigoid, bullous pemphigoid, staphylococcal scalded skin syndrome, chemotherapy-induced stomatitis.

Sources: StatPearls; ScienceDirect (S0365059620306310); Accuracy of IIF, ScienceDirect 0190962295900667.

11. Outcome/Prognosis

• Mortality: 70–90% (StatPearls cites "approaching 90%"); one large hematologic-malignancy-associated cohort (n=144) reported an overall mortality rate of 57%. Most patients die within one year of diagnosis.
• Causes of death: widespread cutaneous infection/sepsis (loss of skin barrier), progression of the underlying malignancy, and bronchiolitis obliterans-related respiratory failure — the latter is frequently cited as the single most common proximate cause of death
• Adverse prognostic factors: keratinocyte necrosis on histology, erythema multiforme-like or TEN-like or bullous-pemphigoid-like cutaneous presentation, extensive mucocutaneous disease at presentation, presence of envoplakin autoantibodies, and development of bronchiolitis obliterans
• Favorable factors: resectable/benign underlying tumor (localized Castleman disease, encapsulated thymoma) is associated with markedly better outcomes than diffuse lymphoproliferative malignancy
• Bronchiolitis obliterans specifically: affects 27–93% of patients across studies (StatPearls cites 30–90%); may require lung transplantation in severe cases
• Complication burden: irreversible blindness (ocular scarring), fluid/electrolyte derangement from cutaneous erosions, malnutrition from oral involvement (often requiring NG feeding), contractures requiring rehabilitation

Sources: Risk factors for death, PMID:30981429; PMC9060127 — BO requiring lung transplant; StatPearls.

12. Treatment

First-Line

High-dose systemic corticosteroids remain first-line therapy for PNP disease control (StatPearls; 2025 systematic review). NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to corticosteroid class (e.g., NCIT:C2280 Prednisone / NCIT:C2322 Corticosteroid class).

Steroid-Sparing / Immunosuppressive Agents

• Azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide — added for steroid-refractory disease
• NCIT: NCIT:C15632 (Chemotherapy) or NCIT:C15986 (Pharmacotherapy) + therapeutic_agent

Biologics

• Rituximab (anti-CD20 monoclonal antibody) — shown efficacious particularly in lymphoproliferative-malignancy-associated PNP; NCIT: NCIT:C1932 (Rituximab); therapeutic_modality: MONOCLONAL_ANTIBODY
• Alemtuzumab (anti-CD52) — used in select cases
• A 2025 systematic review (Advances in Rheumatology) of rituximab + IVIG combination therapy across autoimmune bullous disease found positive outcomes in all but one reported PNP case, though infection risk (e.g., P. jirovecii pneumonia) was noted as a safety concern

Intravenous Immunoglobulin (IVIG)

Used both as adjunct therapy and, notably, peri-operatively (before/after surgical resection of the underlying tumor) — proposed to reduce bronchiolitis-obliterans risk by neutralizing released autoantibodies at the time of tumor lysis. NCIT: NCIT:C15986/therapeutic_agent immunoglobulin.

Plasmapheresis

Used adjunctively in refractory/severe disease.

Malignancy-Directed Therapy

Early diagnosis and definitive treatment of the underlying neoplasm is paramount — surgical resection for solid/localized tumors (thymoma, Castleman disease), and lymphoma/CLL-directed chemoimmunotherapy (e.g., R-CHOP regimens) for lymphoproliferative disease. Notably, mucocutaneous disease does not always parallel malignancy treatment response.

Supportive/Wound Care (burn-unit level)

Occlusive hydrating dressings, warm-water compresses, low-adhesive/petrolatum dressings, silver antimicrobial dressings, topical corticosteroids/calcineurin inhibitors, triamcinolone gel and analgesic mouthwash for oral lesions, nasogastric feeding, pressure-ulcer prevention, antiseptic care, and systemic antibiotics for secondary infection.

Multidisciplinary Team

Oncology, dermatology, ophthalmology, pulmonology, gastroenterology, urology, infectious disease, wound care nursing, nutrition, and mental health support.

Experimental / Emerging

Lung transplantation has been reported for end-stage bronchiolitis obliterans in PNP associated with Castleman disease. Newer B-cell-depleting agents used in refractory classic pemphigus (e.g., inebilizumab) are an area of emerging interest but lack dedicated PNP data.

Sources: StatPearls; Advances in Rheumatology systematic review, 2025; PMC9060127; International Journal of Hematology — R-CHOP long-term survival case.

13. Prevention

There is no established primary prevention strategy for PNP, as it arises unpredictably in association with an underlying neoplasm. The literature emphasizes: - Secondary prevention / early detection: prompt malignancy workup (CBC, LDH, flow cytometry, imaging) in any patient presenting with refractory mucocutaneous erosions and a polymorphous eruption, since PNP precedes malignancy diagnosis in ~30% of cases - Tertiary prevention: perioperative IVIG administration around tumor resection, proposed to blunt autoantibody-mediated bronchiolar injury and reduce bronchiolitis obliterans risk - Genetic counseling is not applicable given the non-Mendelian, acquired nature of the disease - Ophthalmology and pulmonology surveillance are recommended early in the disease course to catch ocular scarring and early bronchiolitis obliterans before irreversible damage occurs

14. Other Species / Natural Disease

PNP is one of the few paraneoplastic autoimmune blistering diseases with documented spontaneous veterinary analogs: - Dogs: paraneoplastic pemphigus has been reported in association with splenic sarcoma and other neoplasms; canine disease shares clinical and immunopathologic features with human PNP (Elmore et al. 2005, Vet Pathol) - Cats and horses: also reported, reviewed comprehensively alongside canine/feline/equine pemphigus vulgaris and pemphigus vegetans in a 2020 BMC Veterinary Research review (PMID:33228633; PMC7686683) - Prognosis in veterinary PNP is described as "grave," paralleling the poor human prognosis; treatment follows similar high-dose glucocorticoid ± immunosuppressant principles as pemphigus vulgaris/vegetans in animals, though PNP itself is noted as rare in dogs specifically associated with neoplasia

NCBI Taxon: dog (NCBITaxon:9615), cat (NCBITaxon:9685), horse (NCBITaxon:9796). No OMIA (Online Mendelian Inheritance in Animals) entry was surfaced, consistent with PNP's non-Mendelian, acquired etiology in animals as in humans.

15. Model Organisms

• In vivo murine models: Neonatal/adult mouse skin injection models have been used to demonstrate pathogenicity of PNP autoantibodies — specifically, anti-desmoplakin C-terminus IgG induced dose-dependent blister formation and acantholysis in mouse skin, with keratinocyte apoptosis observed in neonatal mice after antibody passive transfer (PMC9332891; Frontiers 10.3389/fimmu.2022.886226). These are passive-transfer/induced models, not genetic knockouts, and directly recapitulate acantholysis and blister formation but not the full multi-organ (pulmonary/ocular) phenotype or the underlying neoplasm trigger.
• Related pemphigus vulgaris T-cell models: Dsg3-specific CD4+ T-cell transfer models in mice induce pemphigus-like blistering and interface dermatitis, a histologic hallmark shared with PNP, providing a mechanistic model for the T-cell-mediated component of PNP pathogenesis even though these studies were performed in a pemphigus vulgaris (not PNP) context (JCI 29403; PMC10107879).
• Limitations: No model fully recapitulates the tumor-triggered, multi-antigen (plakin + desmoglein), multi-organ (skin + mucosa + lung) nature of human PNP; existing models isolate single antibody specificities or T-cell clones rather than the full autoimmune repertoire seen clinically. No PNP-specific knockout, transgenic, humanized, or organoid/iPSC model system was identified in this search — representing a clear research gap relative to pemphigus vulgaris, for which more developed genetic mouse models exist.

Summary of Suggested Ontology Term Bindings for KB Curation

Key Citations

• Anhalt/PAMS Part I — Clinical overview and pathophysiology, PMID:37597771 (JAAD, 2024)
• PAMS Part II — Diagnosis and management, PMID:37714216 (JAAD, 2024)
• Paraneoplastic Pemphigus — StatPearls (NCBI Bookshelf NBK546694)
• Oral Paraneoplastic Pemphigus: Scoping Review, PMC11587122
• Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa, PMC6558011
• Anti-desmoplakin C-terminus autoantibodies induce acantholysis in vitro/in vivo, PMC9332891
• Risk factors for death and survival in PNP with hematologic malignancy, PMID:30981429
• Beyond HLA polymorphism — genetic susceptibility to pemphigus, PMC7341728
• Clinical/pathological features of BO requiring lung transplant in PNP with Castleman disease, PMC9060127
• Deep pemphigus in dogs, cats, and horses — comprehensive review, PMID:33228633
• Rituximab + IVIG in autoimmune diseases — systematic review, 2025
• Orphanet: Paraneoplastic pemphigus (ORPHA:63455)
• Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice, JCI 29403

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.